pharma · Severe, Refractory Systemic Lupus Erythematosus · Refractory Progressive Multiple Sclerosis · AUTL
Autolus
Autolus GmbH
Tubulis is a pharma organization headquartered in Munich, DE. It trades on NYSE under ticker AUTL. Primary therapeutic focus areas include Severe, Refractory Systemic Lupus Erythematosus, Refractory Progressive Multiple
Munich, Bayern 81377, DE HQ
117 Employees
Public company Type
AUTL · NYSE Ticker
Company details
- Status
- Public
- HQ
- Munich, Bayern 81377, DE
- Employees
- 117
- Programs
- 16
- Drugs
- 17
- Patents
- 49
AUTO1-SL2
Phase 2 · small molecule · Systemic Lupus Erythematosus with Active Lupus Nephritis
AUTO1-SL2 for Systemic Lupus Erythematosus with Active Lupus Nephritis is a Phase 2 program (small_molecule) at Autolus GmbH with 1 ClinicalTrials.gov record(s).
Internal code AUTO1-SL2
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Autolus GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Systemic Lupus Erythematosus with Active Lupus Nephritis
- Status
- active
- Trials
- 1